Damien McDevitt, PhD, President and CEO of Aspen:

“Parkinson's disease is very personal in nature, and we are working to develop a personal cell therapy for PD. Everyone with Parkinson's has a unique experience, with varied symptoms. We look forward to working closely with the innovative and collaborative teams at Rune Labs and Emerald Innovations to capture a holistic and precise pattern of motor symptom activity over time for people in our screening study.”

Diego Cadavid, MD, Chief Medical Officer of Verge:

“We are thrilled to be the first company to integrate Emerald Innovations’ technology into an ALS study. Given the high unmet need for effective treatments and the complexity of ALS, it is imperative that we leverage innovative technology tools that make it possible to collect dense amounts of unbiased, objective patient function data to properly assess the efficacy and dose-response to VRG50635 early in clinical development.”

Seth Ettenberg, President and CEO of BlueRock Therapeutics:

“Parkinson’s disease is incredibly complex, with symptoms often varying hour to hour through the course of the day. New tools and approaches are needed to ease the reporting burden on patients in trials and to measure and assess disease progression more effectively. We are excited to be working with the pioneering team at Emerald Innovations to harness the power of their digital health technologies to collect an unbiased, objective and continuous measure of disease progression that will help us develop more effective therapies.”

Jana von Hehn, PhD, Chief Scientific Officer of RSRT:

“The Emerald provides direct, objective measures of symptoms captured continuously over days, weeks, months, or longer, generating significantly richer data in shorter timeframes than can be obtained in traditional in-clinic studies. We are excited to continue this important work with Emerald, guided by our Biomarker Consortium and FDA advice, to facilitate more efficient clinical trials and truly effective therapeutics.”